AI Article Synopsis
- - The study aimed to assess how certain genetic variations (HLA-DPβ1 and DRβ1 polymorphisms) interact with levels of beryllium exposure and contribute to the development of beryllium sensitization (BeS) and chronic beryllium disease (CBD).
- - Researchers conducted a matched case-control study, involving 61 CBD cases, 41 BeS cases, and 259 control participants from two facilities where beryllium is processed.
- - Key findings showed that the presence of the DPβE69 variant was linked to BeS and CBD, while the DRβE71 variant might protect against progression from BeS to CBD; however, no clear dose-response relationship with
Article Abstract
Objective: To evaluate interaction of HLA-DPβ1 and DRβ1 polymorphisms with metrics of beryllium exposure, in the development of beryllium sensitization (BeS) and chronic beryllium disease (CBD).
Methods: A matched case-control study of 61 CBD, 41 BeS, and 259 controls from two beryllium-processing facilities.
Results: BES and CBD were significantly associated with presence of DPβE69. Dose response of exposure was not observed for the development of BES and CBD with/without adjustment for DPβE69 (P > 0.05). The DRβE71 polymorphism was more common in BeS than CBD after adjusting for exposure and maybe a protective factor (aOR 0.4, 95% CI 0.2 to 0.9) against the progression of BeS to CBD.
Conclusion: No exposure-response association was found, which may reflect that the workers in this high exposure cohort were above a threshold level where an exposure-response could be observed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/JOM.0000000000001766 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!